Egalet Corporation
| Public (NASDAQ:EGLT),[1] | |
| ISIN | 🆔 |
| Industry | Specialty Pharmaceuticals |
| Predecessor | BM Research A/S [2] |
| Founded 📆 | Værløse, Denmark (1995)[2] |
| Founder 👔 | |
| Headquarters 🏙️ | , Wayne, Pennsylvania , United States [2] |
Number of locations | 3 [3] |
Area served 🗺️ | |
Key people | Tim Walbert (Chairman), Jean-Francois Formela (Board member), Robert Radie (President and CEO), Dr. Roland Gerritsen van der Hoop (CMO), Karsten Lindhardt (VP of R&D and Site Manager) |
| Products 📟 | EG-P042 [4] Parvulet [4] |
| Members | |
Number of employees | |
| 🌐 Website | www.egalet.com (USA) www.egalet.dk (DK) |
| 📇 Address | |
| 📞 telephone | |
Egalet Corporation is a specialty pharmaceutical company focused on the commercialization and development of abuse-resistant formulations of opioids and other pain care drugs. It was founded as a private company in 1995 in Værløse, Denmark, and now operates as a publicly traded American company headquartered in Wayne, Pennsylvania, a suburb west of the city of Philadelphia. The company has offices in the UK, the United States, and Denmark. All research, development, and manufacturing are conducted in the Denmark offices. Egalet trades on the NASDAQ exchange under the trading symbol EGLT, and as of June 2018, is loss-making.[5]
Mechanism of action
Egalet has developed a pill that allows for the controlled release of drugs; it is composed of an inner matrix containing the active ingredient, and an outer coating shell made of proprietary polymers.
The matrix, or inner portion of the pill, contains the dispersed drug. The matrix is designed to erode when it comes into contact with water, but not until the desired release point, to avoid hydrolysis and reduce enzymatic activity.[6][7] The active substance is then released at a zero-order rate, ensuring a steady amount of drug is released over time.[6] This minimizes fluctuations while maximizing the duration the drug remains within the therapeutic window.
The matrix is protected by the outer shell coating, made of a cellulose derivative with thermoplastic properties.[7] This derivative is relatively insoluble in an aqueous solution.[7] The shell also contains a second cellulose derivative that is soluble in an aqueous solution; a plasticizer to improve plasticity and reduce brittleness; and a filler to increase volume.[7] The outer shell protects the inner matrix, which may contain chemically unstable substances, such as those with low melting and boiling points, and water-insoluble compounds.[7] This protective shell significantly extends the shelf life of the substance.[7] The shell composition allows for controlled release of the matrix in both the stomach and intestines, despite varying pH, agitation, etc.[7]
Once ingested, the shell is separated from the matrix through water diffusion, polymer hydration, disentanglement, and dissolution, allowing the matrix to perform its intended function.[6]
By adjusting the shell and matrix compositions, a range of drug formulations and release mechanisms can be achieved. Altering the pill's shape and surface area can also affect release times.[6] The pills are manufactured using injection molding for a single-step creation process.[6]
The matrix
Egalet has perfected the creation of an amorphous state of the active ingredient. An amorphous state requires the formation of a higher energy solid state form.[6] Creating an amorphous dispersion form is crucial for using poorly water-soluble drugs and improving oral bioavailability. The current pill enables control of this amorphous phase and the controlled release of the active substance from the coated matrix system.[6]
The inner matrix is designed for improved bioavailability, especially in situations requiring an insoluble active substance, and to prevent abuse or misuse of the matrix.
The matrix composition includes: 1. A mixture of first (polyethylene glycols and/or polyethylene oxides) and second polymers (block copolymers of ethylene oxide and/or propylene oxide), which provide plasticizing properties.[6] The melting points of the polymers are at most 200 °C.[6] The combination of polyethylene oxides and the block copolymers allows for control of the amorphous state.[6] Examples of the second block polymers include poly(ethylene-glycol-b-(DL-lactic acid-co-glycolic acid)-b-ethylene glycol (PEG-PLGA-PEG), poly((DL-lactic acid-co-glycolic acid)-g-ethylene glycol) (PLGA-g-PEG), poloxamers, and polyethylene oxide-polypropylene oxide (PEO-PPO).[6] 2. A therapeutically and/or diagnostically active substance.[6]
Polymer coating
The first polymer is a polyethylene glycol and/or a polyethylene oxide.[6] Polyethylene glycols (denoted as polyethylene oxides when the molecular weight exceeds approximately 100,000) are mixtures of condensation polymers of ethylene glycol.[6] Preferably, the first polymer has a molecular weight of approximately 35,000 daltons.[6] Mixtures of PEGs can be used to achieve the ideal molecular weight for specific formulations.[6]
References
- ↑ "EGLT:NASDAQ GM Stock Quote - Egalet Corp". Bloomberg.com.
- ↑ 2.0 2.1 2.2 http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=1222227
- ↑ http://www.egalet.com/contact-us/contact-information/
- ↑ 4.0 4.1 http://www.redhillbio.com/news/egalet-and-redhill-biopharma-enter-into-an-exclusive-license-agreement/
- ↑ Smith, Vernon (17 June 2018). Simply Wall Street https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eglt/egalet/news/does-egalet-corporations-nasdaqeglt-recent-track-record-look-strong/. Retrieved 27 June 2018. Missing or empty
|title=(help) - ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 6.13 6.14 6.15 Fischer, et al. "Matrix compositions for controlled delivery of drug substances." U.S. Patent Number 8,298,581. 30 October 2012
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 Bar-Shalom, Daniel. "Controlled release composition." U.S. Patent Number 7,883,722. 8 February 2011.
External links
This article "Egalet" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Egalet. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
